Phase I-II trial of 14 day infusional 6-mercaptopurine in advanced colorectal cancer.
6-Mercaptopurine (6-MP) is a cycle specific antineoplastic agent with a short serum half-life following bolus administration, providing a rationale for continuous infusional administration of the parenteral formulation. 22 patients received 38 courses of 14 day 6-MP infusion. The maximum tolerated dose (MTD) was 35 mg/m2/day (total dose per 14 day cycle 490 mg/m2) with cycles repeated at 28 days. Toxicities included transient hyperbilirubinaemia, leucopenia and thrombocytopenia. 13 evaluable patients with advanced colon cancer resistant to 5-fluorouracil with or without leucovorin received infusional 6-MP at the MTD as part of the phase II study analysis, but no objective responses were observed. Phase II studies in previously untreated patients and longer infusion durations are being evaluated.
Cancer Center of Boston, Massachusetts, USA.
J
J
Lokich
C
C
Moore
N
N
Anderson
M
M
Bern
F
F
Coco
E
E
Dow
T
T
Zipoli
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D015122:Mercaptopurine / Q000008:administration & dosage*; D008875:Middle Aged
D000964:Antimetabolites, Antineoplastic; D015122:Mercaptopurine